Woody Polglase

Edward Polglase is an Equity Research Associate at Bernstein, focusing on US Pharma since September 2022. Edward is also a Contributor for an early-stage gene therapy startup emerging from The Francis Crick Institute, participating in the Nucleate Activator Program as of January 2024. Previous experience includes roles such as Venture Fellow at Hummingbird Ventures, Protein Biochemistry Research Assistant at Vertex Pharmaceuticals, Research Assistant at the University of Cambridge, and Research Analyst at Daten Capital. Edward's academic background includes an MPhil in Therapeutic Sciences from the University of Cambridge and a BSc in Biochemistry from Imperial College London, complemented by a summer finance program at Imperial College Business School.